GHIF supports late-stage innovations for public health challenges such as malaria, cholera, and HIV, with a focus on infectious diseases and maternal/infant health issues in resource-limited settings. The fund employs various investment structures and targets an average investment of $10 million per project. GHIF aims to achieve both social impact objectives and commercial success, with a particular interest in products that have dual market potential and high-volume/low-margin products like essential vaccines. Notable investors include J.P. Morgan, the Bill & Melinda Gates Foundation, and companies like GSK and Pfizer.